PLGA nanoparticle-mediated anti-inflammatory gene delivery for the treatment of neuropathic pain
- PMID: 40186589
- PMCID: PMC12051573
- DOI: 10.1080/17435889.2025.2487410
PLGA nanoparticle-mediated anti-inflammatory gene delivery for the treatment of neuropathic pain
Abstract
Aim: This study aimed to mitigate neuropathic pain behavior in a sciatic nerve transection (SNT)-induced mouse model by delivering anti-inflammatory cytokines - interleukin-4 (IL-4), interleukin-10 (IL-10), and transforming growth factor-beta 1 (TGF-β1) - via poly(d,l-lactic-co-glycolic acid) (PLGA) nanoparticles (NPs).
Materials & methods: Upon gene delivery of IL-4, IL-10, and TGF- β1, the anti-inflammatory effects and induction of microglia M2 polarization were evaluated. Plasmid (IL-4, IL-10, and TGF-β1)-encapsulated PLGA NPs (PLGA@IL-4, PLGA@IL-10, and PLGA@TGF-β1) were synthesized and characterized for size, zeta potential, cellular toxicity, and cellular uptake. The analgesic effect of anti-inflammatory gene delivery using PLGA NPs was then assessed in a mouse model of neuropathic pain.
Results: Gene delivery of IL-4, IL-10, and TGF-β1 showed a significant anti-inflammatory effect in LPS-treated cells and IL-4 strongly promoted microglia M2 polarization in vitro. PLGA NPs successfully delivered the anti-inflammatory cytokine-coding genes into mouse spinal cord cells, specifically targeting microglia. PLGA@IL-4, PLGA@IL-10, and PLGA@TGF-β1 NPs produced analgesic effects in a SNT-induced mouse neuropathic pain model. Notably, PLGA@IL-4 demonstrated the most effective and remarkably long-lasting analgesic effect, strongly enhancing microglia M2 polarization in spinal cord microglia.
Conclusion: Gene therapy using PLGA NPs for overexpression of anti-inflammatory cytokines could be a promising strategy for the treatment of neuropathic pain.
Keywords: IL-10; IL-4; Microglia; TGF-β1; gene delivery; nanoparticle; neuropathic pain; poly(d,l-lactic-co-glycolic acid).
Conflict of interest statement
The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
No writing assistance was utilized in the production of this manuscript.
Similar articles
-
Amitriptyline nanoparticle repositioning prolongs the anti-allodynic effect of enhanced microglia targeting.Nanomedicine (Lond). 2024;19(25):2099-2112. doi: 10.1080/17435889.2024.2390349. Epub 2024 Sep 4. Nanomedicine (Lond). 2024. PMID: 39229790
-
Phosphodiesterase 2A as a Therapeutic Target for Relieving Mechanical Allodynia and Modulating Microglial Polarization in Neuropathic Pain Models Following Spinal Cord Injury.ACS Chem Neurosci. 2025 Jul 16;16(14):2629-2638. doi: 10.1021/acschemneuro.5c00169. Epub 2025 Jun 28. ACS Chem Neurosci. 2025. PMID: 40580118
-
Development of phenylboronic acid functionalized poly (lactic-co-glycolic acid) nanoparticles for novel co-delivery of chemo-herbal combination towards lung cancer: an in silico and in vitro proof of concept.Nanoscale. 2025 Jul 3;17(26):15960-15987. doi: 10.1039/d5nr01407g. Nanoscale. 2025. PMID: 40538375
-
Transcutaneous electrical nerve stimulation (TENS) for neuropathic pain in adults.Cochrane Database Syst Rev. 2017 Sep 14;9(9):CD011976. doi: 10.1002/14651858.CD011976.pub2. Cochrane Database Syst Rev. 2017. PMID: 28905362 Free PMC article.
-
Gabapentin for chronic neuropathic pain and fibromyalgia in adults.Cochrane Database Syst Rev. 2014 Apr 27;2014(4):CD007938. doi: 10.1002/14651858.CD007938.pub3. Cochrane Database Syst Rev. 2014. Update in: Cochrane Database Syst Rev. 2017 Jun 09;6:CD007938. doi: 10.1002/14651858.CD007938.pub4. PMID: 24771480 Free PMC article. Updated.
References
-
- Gadepalli A, Ummadisetty O, Akhilesh, et al. Peripheral mu-opioid receptor activation by dermorphin [D-Arg2, Lys4] (1–4) amide alleviates behavioral and neurobiological aberrations in rat model of chemotherapy-induced neuropathic pain. Neurotherapeutics. 2024;21(1):e00302. doi: 10.1016/j.neurot.2023.10.012 - DOI - PMC - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources